Sensei Biotherapeutics - SNSE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.33
  • Forecasted Upside: 557.56%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.66
▲ +0.052 (8.57%)

This chart shows the closing price for SNSE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sensei Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNSE

Analyst Price Target is $4.33
▲ +557.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Sensei Biotherapeutics in the last 3 months. The average price target is $4.33, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 557.56% upside from the last price of $0.66.

This chart shows the closing price for SNSE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Sensei Biotherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2024CitigroupReiterated RatingBuy ➝ Buy$4.00Low
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00Low
5/24/2024StephensReiterated RatingOverweight ➝ Overweight$5.00 ➝ $5.00Low
5/14/2024StephensInitiated CoverageOverweight$5.00Low
12/4/2023HC WainwrightReiterated RatingBuy$4.00Low
12/13/2022CitigroupInitiated CoverageBuyLow
10/3/2022OppenheimerUpgradeMarket Perform ➝ OutperformLow
3/10/2022Piper SandlerLower TargetOverweight$12.00 ➝ $10.00Medium
7/6/2021Piper SandlerLower TargetOverweight$25.00 ➝ $12.00Low
7/5/2021AlphaValueDowngradeBuyLow
7/1/2021Berenberg BankDowngradeBuy ➝ Hold$12.00High
6/29/2021CitigroupLower TargetBuy$30.00 ➝ $14.00High
6/29/2021OppenheimerDowngradeOutperform ➝ Market Perform$30.00 ➝ $14.00High
3/1/2021OppenheimerInitiated CoverageOutperform$36.00Low
3/1/2021CitigroupInitiated CoverageBuy$30.00Low
3/1/2021Berenberg BankInitiated CoverageBuy$27.00Low
3/1/2021Piper SandlerInitiated CoverageOverweight$25.00Low
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sensei Biotherapeutics logo
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $0.66
Low: $0.61
High: $0.66

50 Day Range

MA: $1.06
Low: $0.59
High: $1.84

52 Week Range

Now: $0.66
Low: $0.51
High: $1.94

Volume

63,000 shs

Average Volume

160,437 shs

Market Capitalization

$16.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Sensei Biotherapeutics?

The following sell-side analysts have issued reports on Sensei Biotherapeutics in the last twelve months: Citigroup Inc., HC Wainwright, and Stephens.
View the latest analyst ratings for SNSE.

What is the current price target for Sensei Biotherapeutics?

3 Wall Street analysts have set twelve-month price targets for Sensei Biotherapeutics in the last year. Their average twelve-month price target is $4.33, suggesting a possible upside of 557.6%. Stephens has the highest price target set, predicting SNSE will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for Sensei Biotherapeutics in the next year.
View the latest price targets for SNSE.

What is the current consensus analyst rating for Sensei Biotherapeutics?

Sensei Biotherapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNSE will outperform the market and that investors should add to their positions of Sensei Biotherapeutics.
View the latest ratings for SNSE.

What other companies compete with Sensei Biotherapeutics?

Other companies that are similar to Sensei Biotherapeutics include Exagen, Cytosorbents, Annovis Bio, Gemini Therapeutics and Rallybio. Learn More about companies similar to Sensei Biotherapeutics.

How do I contact Sensei Biotherapeutics' investor relations team?

Sensei Biotherapeutics' physical mailing address is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. The company's listed phone number is 240-243-8000 and its investor relations email address is [email protected]. The official website for Sensei Biotherapeutics is www.senseibio.com. Learn More about contacing Sensei Biotherapeutics investor relations.